BRIEF published on 10/19/2026 at 07:50, 19 days 20 hours ago Poxel's Financial Performance in the Third Quarter of 2026 Sales Growth Japan Royalties TWYMEEG® Poxel
BRIEF published on 10/19/2026 at 07:50, 19 days 20 hours ago Poxel Announces Third Quarter 2026 Financial Results Poxel Financial Results TWYMEEG® Sales Increase Sumitomo Pharma Projections Royalty Adjustments Japanese Market Performance
PRESS RELEASE published on 10/19/2026 at 07:45, 19 days 20 hours ago Quarterly financial reporting / Third quarter financial report Poxel reports revenue growth in Q3 2026 with TWYMEEG® net sales in Japan surpassing JPY 2.9 billion, up 29% from Q3 2025. Positive net royalties expected for fiscal year 2026 Revenue Net Sales Poxel TWYMEEG Positive Royalties
BRIEF published on 09/03/2026 at 19:20, 2 months 4 days ago Change at the helm of Poxel: Laure-Hélène Mercier appointed President Shareholders Biotechnology Governance Appointment Poxel
BRIEF published on 09/03/2026 at 19:20, 2 months 4 days ago Laure-Hélène Mercier Appointed Chair of Poxel's Board Biotechnology Corporate Governance Board Appointment Poxel Financial Oversight
PRESS RELEASE published on 09/03/2026 at 19:15, 2 months 4 days ago Inside Information / Other news releases Laure-Hélène Mercier appointed as Chair of Poxel's Board of Directors, enhancing governance and financial oversight. Sophie Jacq Lapointe steps down with gratitude. Poxel focuses on metabolic diseases and HCM treatments Governance Metabolic Diseases Poxel Laure-Hélène Mercier HCM
BRIEF published on 07/30/2026 at 21:35, 3 months 8 days ago Poxel: Q2 2026 Results and 2025 Financial Statements Report Revenue TWYMEEG® Poxel Sumitomo Pharma 2025 Accounts
BRIEF published on 07/30/2026 at 21:35, 3 months 8 days ago Poxel Records Positive Turnover amidst Financial Statement Postponement Financial Statements Royalties Poxel TWYMEEG® Sales Debt Valuation
PRESS RELEASE published on 07/30/2026 at 21:30, 3 months 8 days ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 4 months 27 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
Published on 11/06/2026 at 22:15, 1 day 6 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 15 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 15 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 15 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 14 hours 41 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 1 day 8 hours ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 1 day 9 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 1 day 9 hours ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 1 day 9 hours ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 17:54, 1 day 10 hours ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 1 day 10 hours ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
